Poxel S.A. (0RA2.IL)
IOB · EUR · Healthcare · Biotechnology
€0.1646 (-1.79%) as of
Key statistics
- Market cap
- 5.82M
- EPS (TTM)
- -1.0900
- 52-week range
- 0.1310 – 0.4775
- Beta
- 1.45
- Revenue (TTM)
- 1.55M
- Profit margin
- 0.00%
- Volume
- 199.05k
About Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Lyon, France
- Employees
- 15
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.